Synapse - November/December 2018

This month on Synapse

Biosimilars - pricing and reimbursement and the competitive landscape

Our Taylor Wessing and Willke Farr & Gallagher experts discuss the pricing and reimbursement process for biosimilars in the US, the UK, France, Germany and the Netherlands, and the line between competition and a breach of antitrust rules as it applies to this market.

Infringement of second medical use patents in the UK: pregabalin in the Supreme Court

Paul England and Matthew Royle explain the reasoning of the UK Supreme Court Warner-Lambert decision and its implications for how infringement of second medical use claims will be assessed in the UK.

The grant of an SPC for a new therapeutic application

Judith Krens and Marthe Riewald reports a decision from the Netherlands in which a new therapeutic application of a known active substance could qualify for an SPC.

Prescription to patenting: cannabis-derived medicinal products

Paul England examines recent developments allowing prescription of medicinal cannabis for certain conditions.

Can a decision on the UPC be expected soon?

Paul England looks at recent speculation about the Unified Patent Court and Unitary Patent.